Track the companies that matter to you. It's FREE! Click one of these fan favorites to get started: Apple; Google; Ford.



Is Obesity Really a Dangerous Disease?

Don't let it get away!

Keep track of the stocks that matter to you.

Help yourself with the Fool's FREE and easy new watchlist service today.

Obesity drugmakers Arena Pharmaceuticals  (NASDAQ: ARNA  ) , VIVUS  (NASDAQ: VVUS  ) , and Orexigen Therapeutics  (NASDAQ: OREX  ) are three of the mostly hotly debated stocks in the biotech space. The fact that obesity afflicts more than 35% of American adults today defines these companies' massive market opportunity. Investors may not completely understand the nuances of this complex disease, however. For instance, how do clinicians approach the treatment of obesity? Are medications actually an integral part of treatment, or are lifestyle changes more important? Can obesity be cured?

In order to shed light on these topics, Motley Fool health-care analyst Max Macaluso spoke with Dr. Domenica Rubino, a weight management expert and representative of The Obesity Society. In the following segment from their discussion, Dr. Rubino discusses how clinicians define obesity and what other conditions it can lead to.

The relevant video segment can be found between 0:00 and 1:24.

Max Macaluso: Hi, welcome to The Motley Fool. I’m Max Macaluso and today I’m joined by Dr. Domenica Rubino. Welcome.

Dr. Domenica Rubino: Hi, Max. Thank you.

Max: Dr. Rubino is a board-certified physician in obesity medicine, endocrinology, diabetes and metabolism, and internal medicine.

Dr. Rubino: Absolutely.

Max: Today you’re here as a representative of The Obesity Society.

Dr. Rubino: Yes. Thank you.

Max: Dr. Rubino, three of the most popular stocks that our audience follows are Arena, Vivus, and Orexigen. These are three companies that are either developing drugs for the treatment of obesity or already have FDA approved drugs. You’ve also been involved in some of the trials as a clinical investigator.

Today let’s start with a general question. What is obesity?

Dr. Rubino: Obesity is a condition in which we have excess fat -- excess fat cells. The concern about obesity is actually the fat that’s deposited around the abdominal organs, which is reflected in an increase in abdominal waist circumference.

That abdominal obesity actually is what causes problems and diseases. It contributes to heart disease, diabetes, high blood pressure, cholesterol, sleep apnea.

Max: Cancer as well.

Dr. Rubino: Cancer as well, osteoarthritis, liver disease, infertility issues... so it is actually a major health risk to have this excess abdominal weight.

Who will win the obesity drug market?
Can VIVUS pick up its lagging sales and fend off the competition, or will Arena Pharmaceuticals reign supreme in the obesity space? If you're in the dark, grab copies of The Motley Fool's premium research reports on VIVUS and Arena Pharmaceuticals to stay up to date. Senior biotech analyst Brian Orelli gives investors the must-know information, including an in-depth look at the obesity market and reasons to buy and sell both stocks. Click now for an exclusive look at Arena and VIVUS -- complete with a full year of free updates -- today.

Read/Post Comments (1) | Recommend This Article (2)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On March 22, 2013, at 9:13 PM, RSRdriver wrote:

    Why don't you ask Dr. Rubino if it is more dangerous to take a drug that barely works and is linked to cancer in rats! (Belviq!)

Add your comment.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2325993, ~/Articles/ArticleHandler.aspx, 9/27/2016 12:02:41 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated Moments ago Sponsored by:
DOW 18,173.17 78.34 0.43%
S&P 500 2,153.70 7.60 0.35%
NASD 5,286.35 28.85 0.55%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

9/27/2016 11:46 AM
ARNA $1.77 Up +0.04 +2.31%
Arena Pharmaceutic… CAPS Rating: ***
OREX $3.21 Down -0.03 -0.93%
Orexigen Therapeut… CAPS Rating: **
VVUS $1.21 Down -0.03 -2.45%
VIVUS CAPS Rating: **